BlueCrest Capital Management’s TherapeuticsMD TXMD Stock Holding History

BlueCrest Capital Management’s Portfolio TXMD Stock Details TXMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-349	Closed	-$109K	–	1800
2018 Q2	$109K	Buy	+349	New	+$107K	﹤0.01%	1385
2017 Q4	–	Sell	-292	Closed	-$77K	–	1110
2017 Q3	$77K	Buy	+292	New	+$84.4K	﹤0.01%	802
2017 Q2	–	Sell	-222	Closed	-$80K	–	1110
2017 Q1	$80K	Buy	+222	New	+$68.7K	﹤0.01%	686

Other funds holding TXMD

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

DCM

Daruma Capital Management New York $879M AUM 2.11% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VOYA Investment Management Atlanta, Georgia $96.1B AUM 40.06% 1-Year Est. Return

BlueCrest Capital Management's TXMD Position: Q3 2018 in Review

BlueCrest Capital Management sold out of TherapeuticsMD (TXMD) in Q3 2018, closing a stake of 349 shares — an estimated $109K sold.

BlueCrest Capital Management first reported a position in TXMD in Q1 2017 and held it in 3 quarters. The position peaked at $109K in Q2 2018. 155 funds tracked by Wall St. Rank hold TXMD as of Q3 2018.

BlueCrest Capital Management reported no remaining TherapeuticsMD position as of Q3 2018 after selling out during the quarter.
BlueCrest Capital Management sold 349 TherapeuticsMD shares in Q3 2018, an estimated $109K.
BlueCrest Capital Management first reported a position in TherapeuticsMD in Q1 2017 and held it in 3 quarters.
BlueCrest Capital Management's TherapeuticsMD position peaked at $109K in Q2 2018.
155 funds tracked by Wall St. Rank held TherapeuticsMD as of Q3 2018.

Based on BlueCrest Capital Management's 13F filing for Q3 2018, filed 14 Nov 2018.